

DEVELOPMENT AND EVALUATION OF TRANSDERMAL PATCH CONTAINING COLCHICINE

Suraj B. Meshram, G. N. Dhembre*, U. T. Jadhao, S. T. Thoke, S. A. Wathore and Rathod D. A.

Department of Pharmaceutics SV.P. College of Pharmacy, Hatta, Dist. Hingoli, Maharashtra.

Article Received: 06 August 2024 | Article Revised: 29 August 2024 | Article Accepted: 20 September 2024

*Corresponding Author: G. N. Dhembre

Department of Pharmaceutics SV.P. College of Pharmacy, Hatta, Dist. Hingoli, Maharashtra.

DOI: <https://doi.org/10.5281/zenodo.13870934>

How to cite this Article: Suraj B. Meshram, G. N. Dhembre, U. T. Jadhao, S. T. Thoke, S. A. Wathore and Rathod D. A. (2024). DEVELOPMENT AND EVALUATION OF TRANSDERMAL PATCH CONTAINING COLCHICINE. World Journal of Pharmaceutical Science and Research, 3(5), 182-191. <https://doi.org/10.5281/zenodo.13870934>



Copyright © 2024 G. N. Dhembre | World Journal of Pharmaceutical Science and Research.

This is an open-access article distributed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0)

ABSTRACT

The present research work was intended to prepare transdermal patch containing Colchicine as a model drug. Matrix type of colchicine containing transdermal patch was prepared by solvent casting method using three rate controlling polymers like HPMCK4M, ethyl cellulose and PVPK30. Fixed concentration (2%) of all three polymers was utilized for the preparation of patch. Compatibility study of drug with the excipients was determined by I.R. Spectroscopy, Thickness of the patch was measured by using screw gauge. The thickness of prepared patch was found in the range of 0.310 to 0.315 mm. Batch F3 showed highest thickness of patch. The weight of the prepared transdermal patches for different formulations ranged between 52.14 ± 1.20 to 55.70 ± 1.98 mg. The percentage of drug content of formulation batch F1 to F7 varied between 94.04 ± 1.23 to $97.26 \pm 0.31\%$. The folding endurance value for all batch formulations was found within range of 64 to 87. Patches formulated with ethyl cellulose (F2) showed the patch formulation F1, F2 and F3, formulated with HPMC, ethyl cellulose, and PVP K30, without addition of permeation enhancer in fixed concentration i.e. 2%, showed drug release of 72.16 ± 0.33 , 61.12 ± 1.40 and $66.53 \pm 0.62\%$ at the end of 24 hrs respectively. The developed optimized matrix type transdermal patch formulation was found to be stable during the stability study for the period of 3 month indicating good stability of the product.

KEYWORDS: Colchicine, HPMC, Transdermal Patch, folding endurance etc.

INTRODUCTION

Transdermal drug delivery systems (TDDS) represent a pivotal advancement in pharmaceutical technology, offering a non-invasive and convenient means of administering therapeutic agents through the skin for systemic distribution. Unlike conventional routes of drug administration such as oral ingestion or injections, transdermal delivery bypasses the gastrointestinal tract and avoids first-pass metabolism, potentially enhancing drug bioavailability and therapeutic

efficacy while minimizing systemic side effects. This innovative approach utilizes the skin's unique properties as a barrier and a reservoir, allowing for controlled release of medication over extended periods, thus improving patient compliance and overall therapeutic outcomes.^[1] Transdermal Drug Delivery System (TDDS) are defined as self-contained, discrete dosage which is also known as patches. A transdermal patch or a skin patch is a medicated adhesion with minimal inter and intra patient variation. The main objective of transdermal drug delivery system is to deliver drugs in to systemic circulation in to the skin through skin at predetermined rate with minimal inter and intra patient variation.⁴⁻⁶ That will improve bioavailability, more uniform plasma levels, longer duration of action resulting in a reduction in dosing frequency, reduced side effects and improved therapy due to maintenance of plasma levels up to the end of the dosing interval compared to a decline in plasma levels with conventional oral dosage forms.^[2]

The development of transdermal delivery systems has revolutionized the treatment of various medical conditions ranging from chronic pain management to hormone replacement therapy. By harnessing the principles of diffusion, permeation, and drug partitioning across the skin layers.^[3,4]

The skin acts as a formidable barrier to the penetration of drugs and other chemicals; it does have certain advantages which make it an alternative route for systemic delivery of drugs. Transdermal drug delivery system involves the passage of substances from the skin surface through the skin layers, into the systemic circulation. The skin has been commonly used as a site for topical administration of drugs, when the skin serves as a port for administration of systemically active drugs. The drug applied topically is distributed following absorption, first into the systemic circulation and then transported to the target tissue, which can be relatively remote from the site of drug application to achieve its therapeutic action.^[5,6]

MATERIALS AND METHOD

Materials

Colchicine was received as a gift sample from Cipla Ltd, Mumbai, India. HPMC received from Colorcon asia pvt Ltd Goa. All other materials like PEP, TWEEN 80, PEG200, Piperine was of analytical grade and procured from commercial sources.

Method

Formulation of Colchicine Transdermal Patch

Matrix type of colchicine containing transdermal patch was prepared by solvent casting method using three rate controlling polymers like HPMCK4M, ethyl cellulose and PVPK 30. Fixed concentration (2%) of all three polymers were utilized for the preparation of patch. Firstly, required amount of polymer were weight accurately and dissolved in 10 ml of solvent mixture (Chloroform and water in 1:1) ratio under mechanical stirring at 60° C, so as to form uniform polymeric solution. Drug colchicine was weighed accurately and was dissolved separately in a mixture of surfactant (Tween 80) and plasticizer PEG 200 (40 % of polymer weight), according to Table 1. The drug solution was then added to the polymeric solution. Triethanolamine was added dropwise to above mixture in order to achieved the required skin pH condition (6.5 to 7). Above formulation mixture was then further mixed under mechanical stirring at 400 rpm (Remi, India) at a lower temperature 50 °C. In order to see the effect of natural permeation enhancer on permeation rate of drug, the colchicine in different concentration was subsequently added to the polymeric mixture in batch F4, F5, F6 and F7. Finally, patches were obtained by casting the solution in pre lubricated petri dish (40cm²) and were allow to dry

by placing inverted funnel on it, so as to facilitated controlled drying for 24 hours at room temperature. The dry films were removed and cut in required size (2x2cm) and then wrapped in aluminium foil and kept in a dessicator until used.^[7,8,9] The details for the formulation of Colchicine transdermal patch was shown in table 1.

Table 1: Composition of Colchicine Transdermal Patch.

Batch Code	F1	F	F3	F4	F5	F6	F7
Colchicine(mg)	25	2	25	25	25	25	25
HPMC K4 M	2	-	-	2	2	2	2
Ethyl Cellulose (%)	-	2	-	-	-	-	-
PVPK-30 (%)	-	-	2	-	-	-	-
Tween80(ml)	0.1	0.	0.1	0.1	0.1	0.1	0.1
PEG200 (%)	40	4	40	40	40	40	40
Piperine (%)	-	-	-	0.2	0.5	0.7	1
Triethanolamine	q.s	q.	q.s	q.s	q.s	q.s	q.s
Chloroform: Water	10	1	10	10	10	10	10

EXPERIMENTALWORK

Pre formulation Studies

Pre formulation research was therefore done on the drug sample in order to identify it and determine compatibility. Comprehensive pre formulation data enable rational decision-making regarding formulation design, excipient selection, and process optimization to ensure the development of safe, effective, and stable drug products.

UV Spectroscopy

A stock solution of Colchicine was prepared by using phosphate buffer pH 7.4. Then UV Spectrum was scanned in the range 200-400nm by using Shimadzu 1601.

Drug Excipients Compatibility Studies

Compatibility study of drug with the excipients was determined by I.R. Spectroscopy (Shimadzu, Japan). The pellets were prepared at high compaction pressure by using KBr and the ratio of sample to KBr is 1:100. The pellets thus prepared were examined and the spectra of the drug and other ingredients in the formulations were compared with that of the pure drug.

Evaluation of Transdermal Patches Thickness

Thickness of the patch was measured by using screw gauge. The reading of thickness was determined at three different points and average thickness was determined.^[10]

Weight Variation

10 patches from each formulation were weighed individually and the average weight was calculated. The individual weight should not deviate significantly from the average weight.^[11]

Drug Content

A specified area 2x2cm of patch was dissolved in mixture of chloroform and methanol. It was closed and shaken vigorously for 24 hours in a shaker. The resulting solution was filtered and the amount of drug present in the filtrate was determined by using UV spectrophotometer at 246 nm.^[12]

Folding endurance

Folding endurance of the patches was determined by repeatedly folding one patch at the same place till it either breaks or develops visible cracks on folding number of times manually, which was considered satisfactory to reveal good patch properties. This is important to check the ability of sample to withstand folding. This also gives an indication of brittleness. The number of times the films could be folded at the same place without breaking gives the value of folding endurance.^[13]

Surface pH

The patches were allowed to swell by keeping them in contact with 0.5ml of double distilled water for 1h in glass tubes. The surface pH was then noted by bringing a combined glass electrode near the surface of the patch and allowing it to equilibrate for 1 min.

Percentage Moisture Uptake

The patches were weighed accurately and placed in a desiccators where a humidity condition of 80-90 % RH was maintained by using saturated solution of potassium chloride. The patches were kept until uniform weight is obtained, then taken out and weighed. The percentage of moisture uptake was calculated as the difference between final and initial weight with respect to initial weight.^[14]

Percentage Moisture Loss

The prepared films are weighed individually and kept in a desiccators containing calcium chloride at room temperature for 24 h. The films are weighed again after a specified interval until they show a constant weight. The percent moisture content is calculated as the difference between final and initial weight with respect to final weight. The following formula was utilised to calculate the percentage moisture loss.

In Vitro Release Studies

The release studies were performed using Franz diffusion cell, generally comprise of two compartments, one containing the active donor compartment and the other containing receptor solution (receptor compartment), separated by barrier i.e. membrane. The cell consisted of sampling port and temperature maintaining jacket. The outlet and inlet was connected with latex tube so the jacket had stagnant water inside and heat was provided by hotplate. The stainless steel pin was used to stir the receptor solution using magnetic stirrer. A dialysis cellulose membrane was used as artificial membrane and was placed on receptor compartment and both compartments held tight by clamps. Phosphate buffer pH 7.4 was used as receptor medium. The volume of diffusion cell was 10 ml and stirred with bent stainless steel pin. The temperature was maintained at $37 \pm 1^\circ\text{C}$ with the help of hot plate. The study was carried out for 24 hours and at predetermined time interval 1 ml sample was withdrawn and the same volume of phosphate buffer pH 7.4 was added to receptor compartment to maintain sink conditions. The withdrawn sample was analysed spectrophotometrically at 246 nm.^[15,16]

Stability Studies

The purpose of stability study is to provide evidence on the quality of a drug substance or drug product which varies with time under the influence of a variety of environmental factors such as temperature, humidity and light. One formulation was selected for stability studies on the basis of physicochemical characteristics, in vitro drug release of the formulations. The formulation was subjected to accelerated stability studies as per ICH (The International Conference

Thickness

Thickness of the patch was measured by using screw gauge. The reading of thickness was determined at three different points and average thickness was determined. The thickness of prepared patch was found in the range of 0.310 to 0.315 mm. Batch F3 showed highest thickness of patch. Low standard deviation values indicate low variation and uniformity in the formulation. The results were shown in table 2.

Weight Variation

10 patches from each formulation were weighed individually and the average weight was calculated. The weight of the prepared transdermal patches for different formulations ranged between 52.14 ± 1.20 to 55.70 ± 1.98 mg. The variation in weight uniformity of the prepared patches was found within acceptable range. The results were shown in table 2.

Drug Content

Drug content of the patch was carried out to ascertain that the drug is uniformly distributed into the formulation. The percentage of drug content of formulation batch F1 to F7 varied between 94.04 ± 1.23 to $97.26 \pm 0.31\%$. The percentage drug content for all batch formulations was within acceptable limit and indicated good drug containing capability. The results were shown in table 2.

Folding endurance

Folding endurance of the patches was determined by repeatedly folding one patch at the same place till it either breaks or develops visible cracks on folding number of times manually. The folding endurance of batch F1 to F7 was measured manually and data were shown in the table 2 and figure 4. The folding endurance value for all batch formulations was found within range of 64 to 87. Patches formulated with ethyl cellulose (F2) showed less folding endurance value, while those patches prepared with HPMC polymer, gives flexible patch as compared to ethyl cellulose and PVP K 30 and showed higher folding endurance values. HPMC impart higher flexibility to patches. Among the formulation batch F7 showed highest folding endurance. Overall all batch formulation gives satisfactory folding endurance values. The results indicate that the patches would not break and would maintain their integrity with general skin folding when used.




Figure 4: Folding endurance values of Batch formulation F1 to F7.

Surface pH

The surface pH of all patches were determined and was found in the range of 6.6 to 6.8, ensuring compatibility of prepared patch formulation with skin. The results were shown in table 2.

Percentage Moisture Uptake

The percentage moisture uptake for all patch formulation was found in between 7.06 ± 0.83 to 8.32 ± 0.72 . Batch F3 showed highest moisture uptake, while F7 showed minimum value, compare to others. All three hydrophilic polymers showed certain amount of moisture absorption. Moisture uptake for all batch formulation was in limit, which generally required because higher moisture uptake can be liable for microbial growth. The results of percentage moisture uptake value for all batch formulations was shown in table 2.

Percentage Moisture Loss

The Percentage Moisture Loss for prepared patch formulation was found to be between 2.06 ± 0.20 to $3.16 \pm 0.22\%$. Patches prepared with PVPK30 (F3) showed highest percentage loss. The value of % moisture loss for all batch formulation was in limit, which helps to protect the patch to become brittle during storage.

Table 2: Evaluation of Colchicine Transdermal Patches (F1 to F7).

Batch	Thickness (mm) \pm SD*	Weight Variation (mg) \pm SD*	Drug content (%) \pm SD*	Folding Endurance \pm SD*	Surface pH (%)	% Moisture Uptake	% Moisture Loss
F1	0.310 \pm 0.021	52.14 \pm 1.20	95.23 \pm 1.06	86.16 \pm 3.78	6.6	7.10 \pm 0.64	2.10 \pm 0.21
F2	0.314 \pm 0.011	55.20 \pm 2.14	94.04 \pm 1.23	64.33 \pm 4.56	6.7	6.20 \pm 0.45	2.45 \pm 0.15
F3	0.315 \pm 0.014	54.62 \pm 1.61	96.31 \pm 1.36	78.15 \pm 5.19	6.6	8.32 \pm 0.72	3.16 \pm 0.22
F4	0.312 \pm 0.012	53.28 \pm 1.06	95.30 \pm 1.14	82.26 \pm 4.64	6.7	7.13 \pm 1.08	2.24 \pm 0.10
F5	0.314 \pm 0.018	54.42 \pm 1.38	96.14 \pm 0.66	85.10 \pm 3.80	6.6	7.22 \pm 0.40	2.45 \pm 0.14
F6	0.312 \pm 0.015	55.12 \pm 2.17	95.44 \pm 0.61	84.22 \pm 4.14	6.8	7.18 \pm 0.57	2.06 \pm 0.20
F7	0.312 \pm 0.008	55.70 \pm 1.98	97.26 \pm 0.31	87.31 \pm 2.27	6.8	7.06 \pm 0.83	2.18 \pm 0.17

*All values are mean \pm SD (n=3)

In Vitro Drug Release Study

The drug release from the prepared transdermal patch formulation was determined using Franz diffusion cell apparatus for the period of 24hrs. Phosphate buffer solution pH 7.4 was used as diffusion medium. The results of colchicine drug release from patch formulation were shown in table 3. The graph was plotted between percentage drug release and time and it was shown in figure 5.

The patch formulation F1, F2 and F3, formulated with HPMC, ethyl cellulose, and PVP K30, without addition of permeation enhancer in fixed concentration i.e. 2%, showed drug release of 72.16 ± 0.33 , 61.12 ± 1.40 and $66.53 \pm 0.62\%$ at the end of 24 hrs respectively. Patch prepared with ethyl cellulose (F2) show lowest amount of drug release as compared to HPMC and PVP K30, while patch prepared using HPMC (F1) showed optimum amount of drug release in 24 hr and hence selected further for the preparation of patch with natural permeation enhancer (Piperine). Patch formulation F4, F5, F6 and F7 prepared with HPMC alone with varying concentration of piperine as permeation enhancer (0.25%, 0.5%, 0.75% and 1% to polymer weight) showed drug release of 78.45 ± 0.44 , 82.51 ± 0.94 , 86.43 ± 1.04 and $92.48 \pm 0.30\%$ respectively. From the study it was observed that, drug release of colchicine was improved by addition of permeation enhancer piperine. As the concentration of piperine increases, the rate of drug release from the patch was also found to be increased. Drug release study clearly demonstrated that incorporation of

piperine as permeation enhancer significantly improved the drug release. Among the formulations, batch F7 formulated with HPMC(2%) along with piperine (1%) showed controlled drug release over a period of 24 hr when compare with other formulations and hence was selected as optimized formulation.

Table 3: *In-vitro* drug release study of Colchicine transdermal patch.

Time (hr)	F1	F2	F3	F4	F5	F6	F7
0	0	0	0	0	0	0	0
1	10.21±0.76	5.26±0.23	7.24±2.16	13.78±1.24	15.25±0.21	15.84±0.34	16.34±0.77
2	15.56±1.12	10.44±1.98	12.54±0.65	19.3±1.07	22.45±2.23	23.67±0.33	25.65±0.83
3	19.14±0.56	13.56±0.67	15.59±0.25	22.17±0.33	25.56±1.12	28.1±1.14	31.45±1.45
4	24.32±0.44	18.45±1.04	20.1±0.37	26.3±0.59	28.7±0.51	32.54±0.67	36.51±1.34
5	29.78±0.36	23.12±0.54	25.61±1.52	31.23±0.75	34.18±1.32	37.12±0.88	43.55±0.60
6	35.2±1.20	27.34±0.80	29.21±1.28	37.18±1.94	40.2±0.43	46.43±0.71	50.52±0.71
7	40.7±0.65	31.2±0.31	34.14±0.48	42.4±0.61	44.13±0.65	49.35±0.55	55.4±0.20
8	47.41±2.07	38.5±0.55	39.13±0.78	48.31±0.88	52.45±0.70	58.27±1.22	63.23±0.18
9	50.66±1.42	41.2±0.42	44.24±1.13	55.24±0.58	58.7±0.27	64.3±2.20	68.53±0.72
10	55.26±0.78	44.22±2.02	49.88±0.88	59.12±1.40	63.08±1.21	67.42±0.76	73.12±0.42
11	60.14±1.62	47.31±1.27	52.51±0.20	63.26±2.05	65.41±0.55	70.12±1.45	78.67±0.38
12	63.31±1.54	50.70±0.91	55.22±1.32	67.42±1.22	70.11±1.60	76.92±2.06	83.45±0.30
24	72.16±0.33	61.12±1.40	66.53±0.62	78.45±0.44	82.51±0.94	86.43±1.04	92.48±0.30

All values are mean ± SD (n=3)




Figure 5: *In vitro* Release Profile of Formulations F1 to F3.




Figure 6: *In Vitro* Release Profile of Formulations F4 to F7.




Figure 7: *in Vitro* Release Profile of Formulations F1 to F7.

CONCLUSION

The matrix type transdermal patches of colchicine can be effectively prepared by solvent casting method for the treatment of gout. HPMC K4M was found to be effective polymer in the development of transdermal patches of colchicine. All the prepared formulations were showed satisfactory results required for the transdermal patch type of products. IR- spectroscopic studies indicate no drug-excipient interaction in formulation. The *in vitro* release profile of all the prepared patches formulations were showed to extend the drug release over a longer duration. Piperine was found to be showed excellent natural drug permeation enhancing ability, when incorporated in transdermal patch formulation. Comparing the entire batch, F7 was consider as the ideal formulation which on the basis of evaluation parameters. Future details investigation is required to establish *in vivo* efficiency of colchicine contained transdermal patch and long term stability study need to be confirming the stability of colchicine transdermal patch.

REFERENCES

1. Chein YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker, 1992; p. 1-2, 301-50.
2. Tyle P. Drug Delivery Devices. Fundamentals and Applications. New York: Marcel Dekker, 1998. p. 385-417.
3. Desai BG, Anna malai AR, Divya B, Dinesh BM. Effect of enhancers on permeation kinetics of captopril for transdermal system. Asian J Pharm, 2008; 2: 35-7.
4. Langer R. Transdermal drug delivery: past progress, current status and future prospects. Adv Drug Del Rev, 2004; 56(5): 557-8.
5. Jadhao Umesh T, Rathod Sayali P, Dhembre Gunesh N, Sable Shital D., Formulation and critical evaluation of piroxicam gel., The Pharma Innovation Journal, 2021; 10(3): 89-94.,
6. Cleary GW, Beskar E. Transdermal and transdermal like delivery system opportunities; Today and the Future. Pharmatech 2003; 82-8.
7. Ryan D Gand Peterson TA. 4 Myths about transdermal drug delivery. Drug Del Tech, 2003; 3(4): 1-7.
8. Sheth NS, Mistry RB. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. Journal of Applied Pharmaceutical Science, 2011; 01(03): 96-101.
9. Patel PM, Bhaskar VH. In-vitro, Ex-vivo Skin Permeation and Biological Evaluation of 18-B-Glycyrrhithic Acid Transdermal Patches. International Journal of Pharma Research & Review, August 2015; 4(8): 28-36.

10. Gupta JRD., Irchhiaya R., Garud N., Tripathi P. Formulation and Evaluation of Matrix Type Transdermal Patches of Glibenclamide. *International Journal of Pharmaceutical Sciences and Drug Research*, 2009; 1(1): 46-50.
11. Dharmesh Trivedi, Anju Goyal. Formulation and evaluation of transdermal patches containing dexketoprofen trometamol. *International Journal of Pharmaceutical Chemistry and Analysis*, 2020; 7(2): 87–97.
12. Afzal, S.; Barkat, K.; Ashraf, M. U.; Khalid, I.; Mehmood, Y.; Shah, N. H.; Badshah, S. F.; Naeem, S.; Khan, S. A.; Kazi, M. Formulation and Characterization of Polymeric Cross-Linked Hydrogel Patches for Topical Delivery of Antibiotic for Healing Wound Infections. *Polymers*, 2023; 15: 1652.
13. Saeed, S.; Barkat, K.; Ashraf, M.U.; Shabbir, M.; Anjum, I.; Badshah, S.F.; Aamir, M.; Malik, N.S.; Tariq, A.; Ullah, R. Flexible Topical Hydrogel Patch Loaded with Antimicrobial Drug for Accelerated Wound Healing. *Gels*, 2023; 9: 567.
14. Sridhar BK, Wahid A, Shivakumar S. Preparation and evaluation of transdermal drug delivery system of etoricoxib using modified chitosan. *Indian J Pharm Sci*, 2008; 70(4): 455-60.
15. Liang Fang, TingLi, Changshun Ren, Manli Wang, Lingang Zhao, Ximeng Wang. Optimized preparation and evaluation of indomethacin transdermal patch. *Asian Journal of Pharmaceutical Sciences*, 2007; 2(6): 249-59.
16. Rao RP, Diwan PV, Rao RR. Formulation and evaluation of polymeric films of indomethacin for transdermal administration. *Indian J Pharm Sci*, 1998; 60(3): 169- 7.
17. Singh UV, Pandey S, Udupa N. Preparation and evaluation of flurbiprofen and diclofenac sodium transdermal films. *Indian J Pharm Sci*, 1993; 55(4): 145-7.
18. Jun Shik Choi, Youngah Cho, In Koo Chun, Sun Young Jung, Hyesungwak. Formulation and evaluation of ketorolac transdermal systems. *Drug Deliv*, 2007; 14(2): 69-74.
19. Liang fang, Jing-Ying Zhang, Zhe Tan, Jian Wu, Zhong-Gui He. Influence of ion pairing and chemical enhancers on the transdermal delivery of meloxicam. *Drug DevInd Pharm*, 2009; 35(6): 663-70.
20. Banweer J, Pandey S, Pathak AK. Formulation, optimization and evaluation of matrix type transdermal system of lisinopril dehydrate using permeation enhancers. *J Pharm Res*, 2008; 1(1): 16-22.
21. Pathan IB, Setty CM. Chemical penetration enhancers for transdermal drug delivery systems. *Trop J Pharm Res*, 2009; 8(2): 173-9.
22. Sandip T. Thoke Gunesh N. Dhembre, Vilas N. Deshmukh, Rajeshwar V. Kshirsagar, Umesh T Jadhao, Formulation, characterization and evaluation of Floating hollow Microspheres of Pentoxifylline, *Journal of Pharmaceutical Advanced Research*, 2022; 1784-1791.
23. Y. Krishna Reddy, D. Maheswara Reddy, V. Saroja, S.K. Maimoon. Transdermal Drug Delivery System: A Review. *Research J. Pharma. Dosage Forms and Tech*, 2013; 5(4): 202-12.
24. Scheindlin S. Transdermal Drug Delivery: Past, Present, Future. *Molecular Interventions*, 2004; 4(6): 308, 312.
25. Rao YM, Gannu R, Vishnu YV and Kishan V. Development of nitrendipine transdermal patches for in vitro and ex vivo characterization. *Curr DrugDeliv*, 2007; 4: 69-76.
26. Mao Z, Zhan X, Tang G, Chen S. A new copolymer membrane controlling clonidine linear release in a transdermal drug delivery system. *Int J Pharm*, 2006; 332: 1-5.
27. Aqil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: In vitro characterization. *Acta Pharm*, 2003; 53: 119-25.